VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 9, 2010) - Tekmira Pharmaceuticals Corporation (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics and proprietary delivery technology, announced today its 2010 milestones, which include the progress of multiple RNAi product candidates into clinical development by Tekmira and its partners.
BREA, Calif. – (Feb. 9, 2010) – The Beckman Coulter Antibody Cocktail Preparation Workstation automatically combines antibodies and staining dyes from individual vials into tubes or vials staged on the company’s Biomek* NXp deck. Automating the multi-color flow cytometry analysis preparation process eliminates costly errors associated with manual preparation and improves efficiency. Complex multi-reagent, multi-panel antibody staining cocktails** are prepared with precision and accuracy.
Winston-Salem, North Carolina—February 8, 2010— Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an ?6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson’s Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months.
Reykjavik, Iceland, 9 February 2010 ? Actavis Group, the international generic pharmaceuticals company, has pledged over EUR1.5M worth of pharmaceuticals and cash to the relief efforts following the recent devastating earthquake in Haiti.
LAUSANNE, Switzerland, February 9/PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect.
Toronto, ON (February 9, 2010) - Tibotec, a division of Janssen-Ortho Inc., announced that Health Canada has approved Prezista (darunavir) for use in children with HIV between the ages of six and 18, dosed twice daily in combination with ritonavir and other antiretroviral agents. Prezista is a protease inhibitor that works by blocking an enzyme critical for the growth of the virus within the body.
NEW YORK--(BUSINESS WIRE)--Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and care delivery.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2010 - Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
CAMBRIDGE, Mass., Feb. 9, 2010 (AP) -- Biogen Idec Inc. said Tuesday its profit rose 48 percent in the fourth quarter due to higher sales of its drug Tysabri, a treatment for multiple sclerosis and Crohn's disease. The biotechnology company also forecast a profit for this year that is above current Wall Street estimates.
INDIANAPOLIS, Feb. 9, 2010 (STAR)--The top executive of Eli Lilly and Co. saw his total compensation rise last year by 44 percent, to $20.9 million, but the Indianapolis drug maker attributed most of the increase to accounting adjustments and said the actual package was much lower. Without the adjustments, John L. Lechleiter's total compensation would have been $15.9 million, an increase of about 9 percent, the company said.
SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration (the "FDA") informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA").
LEUVEN, Belgium, February 9/PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.
PARIS, Feb. 9 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc. (NASDAQ:CHTT) .
LONDON, Feb. 9 /PRNewswire/ -- Biomarker analysis market has excellent growth potential. The 'omics' revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. Biomarkers have a multitude of applications such as early disease detection, identifying potential drug targets, predicting patient response to medication and accelerating clinical trials.
SILVER SPRING, Md., Feb. 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will release its fourth quarter and annual 2009 financial results before market open on Tuesday, February 16, 2010.
LOS ANGELES, Feb. 9 /PRNewswire/ -- BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide - Osaka in Japan, and adding to BBK's existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone.
CARMEL, Ind., Feb. 9 /PRNewswire/ -- The American Psychiatric Association (APA) has chosen CME Enterprise as the sole medical education partner to prepare and manage all industry-supported symposia (ISS) programming at its annual meeting in New Orleans, Louisiana, from May 22-26, 2010.
|
